JP2023503797A5 - - Google Patents

Info

Publication number
JP2023503797A5
JP2023503797A5 JP2022520680A JP2022520680A JP2023503797A5 JP 2023503797 A5 JP2023503797 A5 JP 2023503797A5 JP 2022520680 A JP2022520680 A JP 2022520680A JP 2022520680 A JP2022520680 A JP 2022520680A JP 2023503797 A5 JP2023503797 A5 JP 2023503797A5
Authority
JP
Japan
Prior art keywords
composition according
sequence
nucleic acid
acid sequence
mgs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044510 external-priority patent/WO2021066931A1/en
Publication of JP2023503797A publication Critical patent/JP2023503797A/ja
Publication of JP2023503797A5 publication Critical patent/JP2023503797A5/ja
Priority to JP2025132078A priority Critical patent/JP2025166082A/ja
Pending legal-status Critical Current

Links

JP2022520680A 2019-10-01 2020-07-31 分子ガイドシステムペプチド及びその使用 Pending JP2023503797A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025132078A JP2025166082A (ja) 2019-10-01 2025-08-07 分子ガイドシステムペプチド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908687P 2019-10-01 2019-10-01
US62/908,687 2019-10-01
PCT/US2020/044510 WO2021066931A1 (en) 2019-10-01 2020-07-31 Molecular guide system peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025132078A Division JP2025166082A (ja) 2019-10-01 2025-08-07 分子ガイドシステムペプチド及びその使用

Publications (2)

Publication Number Publication Date
JP2023503797A JP2023503797A (ja) 2023-02-01
JP2023503797A5 true JP2023503797A5 (cg-RX-API-DMAC10.html) 2023-08-07

Family

ID=75337452

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520680A Pending JP2023503797A (ja) 2019-10-01 2020-07-31 分子ガイドシステムペプチド及びその使用
JP2025132078A Pending JP2025166082A (ja) 2019-10-01 2025-08-07 分子ガイドシステムペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025132078A Pending JP2025166082A (ja) 2019-10-01 2025-08-07 分子ガイドシステムペプチド及びその使用

Country Status (6)

Country Link
US (1) US20220380764A1 (cg-RX-API-DMAC10.html)
EP (2) EP4360655A3 (cg-RX-API-DMAC10.html)
JP (2) JP2023503797A (cg-RX-API-DMAC10.html)
CN (1) CN115243699A (cg-RX-API-DMAC10.html)
AU (2) AU2020357455B2 (cg-RX-API-DMAC10.html)
WO (1) WO2021066931A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121080A4 (en) 2020-03-18 2024-08-07 SRI International MOLECULAR TRANSPORT SYSTEM TO THE CENTRAL NERVOUS SYSTEM
US20240287148A1 (en) * 2021-07-15 2024-08-29 Cornell University Engineered biomolecules for nutrient reprogramming
US12516086B2 (en) 2021-12-21 2026-01-06 Sri International Dual targeting for cell-specific delivery to the central nervous system
WO2025006452A2 (en) * 2023-06-26 2025-01-02 Sri International NEU5GC-LEWISa-TARGETING MOLECULES AND USES THEREOF IN CANCER
WO2025240414A1 (en) * 2024-05-14 2025-11-20 Sri International Cardiomyocyte-specific molecular guidance system peptides and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090110662A1 (en) * 2007-04-30 2009-04-30 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
WO2009089186A2 (en) * 2008-01-05 2009-07-16 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
WO2015168589A2 (en) * 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
WO2019014190A1 (en) * 2017-07-10 2019-01-17 Brown Kathlynn C MOLECULAR GUIDANCE SYSTEM PEPTIDES AND USES THEREOF
EP3652195A4 (en) * 2017-07-10 2021-08-04 SRI International PEPTID-SAPORINE CONJUGATE FOR THE TREATMENT OF CANCER
WO2019017199A1 (ja) * 2017-07-21 2019-01-24 株式会社豊田自動織機 正極活物質

Similar Documents

Publication Publication Date Title
Omidi et al. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin-and oligofectamine-induced gene expression changes in human epithelial cells
JP4974890B2 (ja) ペプチドが結合された、イノシン置換アンチセンスオリゴマー化合物および方法
CN111989113B (zh) 用于治疗癌症的包含向导rna和核酸内切酶作活性成分的药物组合物
Kundu et al. Synthesis of phosphorodiamidate morpholino oligonucleotides using trityl and fmoc chemistry in an automated oligo synthesizer
KR20220044811A (ko) Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기
WO2017099494A1 (ko) Cpf1을 포함하는 유전체 교정용 조성물 및 그 용도
EP2632932A2 (en) Compositions and methods for activating expression by a specific endogenous mirna
JP2018521970A (ja) ペプチドオリゴヌクレオチドコンジュゲート
CN107177591A (zh) 利用CRISPR技术编辑CCR5基因的sgRNA序列及其用途
JP2022023144A5 (cg-RX-API-DMAC10.html)
JP2025081638A5 (cg-RX-API-DMAC10.html)
JP2024511131A5 (cg-RX-API-DMAC10.html)
JP2025516638A5 (cg-RX-API-DMAC10.html)
JP2023085547A (ja) snoRNAの発現抑制剤を有効成分とするがん増殖抑制剤
Staroseletz et al. ‘Dual’peptidyl-oligonucleotide conjugates: Role of conformational flexibility in catalytic cleavage of RNA
Yu et al. Roles of ANP32 proteins in cell biology and viral replication
EP4360655A3 (en) Molecular guide system peptides and uses thereof
US20210332094A1 (en) Novel transcription activator
KR20240040112A (ko) 방법
US20060008464A1 (en) Histone conjugates and uses thereof
US11845934B2 (en) Specific synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing CRISPR mediated genome editing efficiency
EP1618195A2 (en) Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna)
JP6506270B2 (ja) アンチセンスオリゴヌクレオチド組成物
CN102229928B (zh) 人rbbp6基因的小干扰rna及其应用
KR20220005411A (ko) 질환 세포-특이적인 miRNA에 의해 세포 생리 활성 조절 물질의 활성을 조절하는 복합체 및 이를 CRISPR/Cas 시스템에 적용한 질환 특이적 유전자 조작용 복합체